Cetjap-Asin: Comparison Effectiveness Analysis Between ACL Reconstruction and Rehabilitation in Peripheral and Main Capital in Indonesia

Sponsor
Universitas Riau (Other)
Overall Status
Recruiting
CT.gov ID
NCT04748328
Collaborator
(none)
120
1
34
3.5

Study Details

Study Description

Brief Summary

The study was a prospective observational study analysis of cases having complete ACL tear. Study conduct between February 2021 to December 2023. All the patients attending the emergency or Out Patient Department (OPD) of those hospitals with knee injuries were evaluated for an ACL tear. Patients who meet inclusion criteria and give consent for participation in the study will observe for two years. Patient in Arifin Achmad Hospital Pekanbaru will follow rehabilitation treatment and optional delayed reconstruction after 12 weeks, while patient in Gatot Subroto Army Hospital Jakarta will performed early reconstruction treatment. After taking informed consent, all subjects were provided a self-administered patient questionnaire containing International Knee Documentation Committee (IKDC) score, ACL-RSI, Lysholm, and Tegner Activity Level (TAL) scores. These questionnaires will be measured at 0, 12, 24, 48, and 96 weeks. Besides that, all subjects were provided SF12 for measuring utility value by converting to SF6D. Clinical value of the Lachman test, pivot shift test will be performed. One independent orthopedic surgeon will keep all records and evaluate the results. All costs for the treatment will be accounted for.

Condition or Disease Intervention/Treatment Phase
  • Procedure: ACL Reconstruction surgery and Rehabilitation Treatment

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
120 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Comparison Effectiveness Analysis Between ACL Reconstruction and Rehabilitation in Peripheral and Main Capital of Indonesia
Actual Study Start Date :
Mar 1, 2021
Anticipated Primary Completion Date :
Feb 28, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
ACL Reconstruction Group

This group received reconstruction treatment in Gatot Subroto Hospital, Jakarta

Procedure: ACL Reconstruction surgery and Rehabilitation Treatment
ACL Reconstruction surgery is a procedure to treat ACL injury by replacing the torn ligament with another. ACL Rehabilitation treatment is a procedure to treat ACL injury by muscle strengthening and exercise

Rehabilitation Group

This group received rehabilitation treatment with optional delayed reconstruction in Arifin Achmad Hospital, Pekanbaru

Procedure: ACL Reconstruction surgery and Rehabilitation Treatment
ACL Reconstruction surgery is a procedure to treat ACL injury by replacing the torn ligament with another. ACL Rehabilitation treatment is a procedure to treat ACL injury by muscle strengthening and exercise

Outcome Measures

Primary Outcome Measures

  1. Change of Lachman Test [at pre operation (0 month), 3rd month, 6th month, 12th month, 24th month]

    Lachman test was measured by passive movement of the knee at 30 degree of flexion, Grade 1: 3-5mm translation of the tibia Grade 2: 5-10 mm more translation of the tibia Grade 3: translation of the tibia more than 10mm

  2. Change of Pivot shift test [at pre operation (0 month), 3rd month, 6th month, 12th month, 24th month]

    Pivot shift test was measured by valgus and slowly flexion the knee, Grade 1: gentle twisting slide with tibia twisting internally maximally Grade 2: Clunk with tibia in neutral position Grade 3: painless glide for examiner and patient

  3. Total cost of treatment [at 12th month]

    Total cost for surgery treatment or rehabilitation treatment in Rupiah (Indonesian currency). Cost was taken account by direct interview to the patient and direct observation to medical account in the hospital

  4. Change of Questionnaire of International Knee Documentation Committee (IKDC Questionnaire) [IKDC questionnaire was measured at pre operation (0 month), 3rd month, 6th month, 12th month, 24th month]

    IKDC is a subjective patient reported outcome measure for knee specific disease. Scoring in range 0-100, which 0 is lowest score, and 100 is a highest score

  5. Change of Questionnaire of Short Form-12 (SF-12) [SF-12 questionnaire was measured at pre operation (0 month), 3rd month, 6th month, 12th month, 24th month]

    Questionnaire of Short Form-12 (SF-12) is a generic patient reported outcome measure for measuring physical, mental and quality of life of patient according to Ware et al.(1996). Its score ranging from 0 to 100. Higher scores indicate better health status, and a mean score of 50 has been articulated as a normative value for all scales.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 40 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  1. Age between 18 to 40 years

  2. Either sex

  3. Isolated ACL tear not more than 6 weeks old to a previously uninjured knee

  4. Tegner Activitiy Level of 5-9.

Exclusion criteria

  1. Professional athletes or military

  2. Collateral ligament rupture

  3. Full-thickness cartilage lesion visualized

  4. TAL below 5

  5. Meniscal tear grade III on MRI.

  6. Pregnancy

  7. A history of deep vein thrombosis (DVT) or a disorder of the coagulative system

  8. Claustrophobia

  9. General systemic disease affecting physical function, any other condition or treatment interfering with the completion of the trial, including patients with metal devices or motion disorders

  10. Hyperlaxity with Beighton score more than 4

Contacts and Locations

Locations

Site City State Country Postal Code
1 Arifin Achmad Hospital Pekanbaru Riau Indonesia 28133

Sponsors and Collaborators

  • Universitas Riau

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Romy Deviandri, dr, Universitas Riau
ClinicalTrials.gov Identifier:
NCT04748328
Other Study ID Numbers:
  • KET-894
First Posted:
Feb 10, 2021
Last Update Posted:
Apr 28, 2021
Last Verified:
Apr 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 28, 2021